CTOs on the Move

Vascular Biogenics Limited Therapeutics

www.vblrx.com

 
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ICON Laboratories

ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconome

Onconome is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viela Bio

Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.

Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is a clinical stage private biopharma with prodrug platforms that address opioid use disorder. Trypsin-Activated Abuse Protection (TAAP) technology forms an opioid prodrug that can only be activated through a 2-step internal digestive process, and therefore cannot be abused by chewing, snorting or IV administration.

Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people`s lives by learning from the wisdom of their adaptive immune systems. Adaptive`s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated.